Real-world post-progression outcomes for EGFR-mutant advanced NSCLC patients treated with first-line osimertinib. A single-institution series from The Christie
Gomez-Randulfe, I. Mrak, L. Monaca, F. Gomes, F. Taylor, P. Cove-Smith, L. Hughes, S. Lindsay, C. Blackhall, F. Summers, Y.
Gomez-Randulfe, I.
Mrak, L.
Monaca, F.
Gomes, F.
Taylor, P.
Cove-Smith, L.
Hughes, S.
Lindsay, C.
Blackhall, F.
Summers, Y.
Abstract
Description
Date
2025
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Gomez-Randulfe I, Mrak L, Monaca F, Gomes F, Taylor P, Cove-Smith L, et al. Real-world post-progression outcomes for EGFR-mutant advanced NSCLC patients treated with first-line osimertinib. A single-institution series from The Christie. Lung cancer (Amsterdam, Netherlands). 2025 FEB;200. PubMed PMID: WOS:001470424200105. English.